Thomas Borody

Last updated

Thomas J. Borody FRSN (born 1950) is an Australian gastroenterologist.

Contents

In the 1980s Borody contributed to development of a treatment for Helicobacter pylori. During the COVID-19 pandemic he became embroiled in controversy for advocating an ivermectin-based purported "cure" for COVID-19 without transparently declaring his financial interest in it. [1] [2]

Biography

Borody was born in 1950 in Kraków, Poland. His father was a Seventh-Day Adventist minister and the family immigrated to Australia when he was ten years old. [3]

Borody completed both his BSc(Med) and later MB BS degrees at the University of New South Wales, graduating in 1974. He studied Tropical Medicine at Sydney University and later gained practical experience in the Solomon Islands in 1978 in general parasitology and the treatment of malaria, tuberculosis and leprosy before working at St Vincent's Hospital. He undertook postgraduate research at Sydney's Garvan Institute of Medical Research, culminating in his MD, then at the Mayo Clinic in Rochester, Minnesota. After further research on return to Sydney, he was awarded his PhD and then Doctorate in Science.

In 1984, Borody founded the Centre for Digestive Diseases (CDD) in Five Dock, New South Wales, a private day procedure hospital specialising in the diagnosis and treatment of diseases and disorders of the digestive system, with a focus on infective diseases and novel and alternative treatment solutions.

As of 2013, Borody was a board member of RedHill Biopharma, an Israeli pharmaceutical company. [3] He was elected a Fellow of the Royal Society of New South Wales in 2018. [4]

Peptic ulcers

In the 1980s Borody contributed to development of a treatment for Helicobacter pylori that has now been superseded. He and his colleagues developed a "triple therapy" combining bismuth, tetracycline and flagyl. [3]

Fecal microbiota transplantation

Borody has used fecal microbiota transplantation as treatment for Clostridium difficile infection. [5] He has also promoted FMT for all manner of indications, including irritable bowel syndrome, Crohn's disease and ulcerative colitis for which little evidence to support these indications.

COVID-19

In 2020, Borody announced that he had discovered a "cure" for COVID-19: a combination of ivermectin, doxycycline and zinc. In a media interview Borody stated "The biggest thing about this is no one will make money from this". [2]

It later emerged that Topelia Australia, Borody's company, had filed a patent for the drug combination. [2] [6] Borody was publicly accused of not adequately disclosing his conflict of interest. [1] Wendy Lipworth from The University of Sydney's Health Ethics Centre described such behaviour as "blatantly unethical". [1] Borody, via lawyers, denied wrongdoing. [6]

As of 22 December 2021 the Australian Government Department of Health says there is "insufficient evidence to recommend ivermectin, doxycycline and zinc (either separately, or in combination) for the prevention or treatment of COVID-19". [7]

Publications

He has authored over 300 publications and regularly presents at gastroenterology conferences. He is a reviewer for a number of medical journals, including:[ citation needed ]

See also

Related Research Articles

<span class="mw-page-title-main">Gastroenterology</span> Branch of medicine focused on the digestive system and its disorders

Gastroenterology is the branch of medicine focused on the digestive system and its disorders. The digestive system consists of the gastrointestinal tract, sometimes referred to as the GI tract, which includes the esophagus, stomach, small intestine and large intestine as well as the accessory organs of digestion which include the pancreas, gallbladder, and liver. The digestive system functions to move material through the GI tract via peristalsis, break down that material via digestion, absorb nutrients for use throughout the body, and remove waste from the body via defecation. Physicians who specialize in the medical specialty of gastroenterology are called gastroenterologists or sometimes GI doctors. Some of the most common conditions managed by gastroenterologists include gastroesophageal reflux disease, gastrointestinal bleeding, irritable bowel syndrome, inflammatory bowel disease (IBD) which includes Crohn's disease and ulcerative colitis, peptic ulcer disease, gallbladder and biliary tract disease, hepatitis, pancreatitis, colitis, colon polyps and cancer, nutritional problems, and many more.

<span class="mw-page-title-main">Proton-pump inhibitor</span> Class of drugs for reducing stomach acid

Proton-pump inhibitors (PPIs) are a class of medications that cause a profound and prolonged reduction of stomach acid production. They do so by irreversibly inhibiting the stomach's H+/K+ ATPase proton pump.

Peptic ulcer disease (PUD) is a break in the inner lining of the stomach, the first part of the small intestine, or sometimes the lower esophagus. An ulcer in the stomach is called a gastric ulcer, while one in the first part of the intestines is a duodenal ulcer. The most common symptoms of a duodenal ulcer are waking at night with upper abdominal pain, and upper abdominal pain that improves with eating. With a gastric ulcer, the pain may worsen with eating. The pain is often described as a burning or dull ache. Other symptoms include belching, vomiting, weight loss, or poor appetite. About a third of older people have no symptoms. Complications may include bleeding, perforation, and blockage of the stomach. Bleeding occurs in as many as 15% of cases.

<i>Helicobacter pylori</i> Species of bacteria

Helicobacter pylori, previously known as Campylobacter pylori, is a gram-negative, flagellated, spiral bacterium sometimes with a slightly curved rod shape. Its helical or spiral body is thought to have evolved in order to penetrate the mucous lining of the stomach, helped by its flagella, and thereby establish infection. The bacterium was first identified in 1982 by the Australian doctors Barry Marshall and Robin Warren.

<span class="mw-page-title-main">Stomach cancer</span> Cancerous tumor originating in the stomach lining

Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach. Most cases of stomach cancers are gastric carcinomas, which can be divided into a number of subtypes, including gastric adenocarcinomas. Lymphomas and mesenchymal tumors may also develop in the stomach. Early symptoms may include heartburn, upper abdominal pain, nausea, and loss of appetite. Later signs and symptoms may include weight loss, yellowing of the skin and whites of the eyes, vomiting, difficulty swallowing, and blood in the stool, among others. The cancer may spread from the stomach to other parts of the body, particularly the liver, lungs, bones, lining of the abdomen, and lymph nodes.

<span class="mw-page-title-main">Barry Marshall</span> Australian physician (born 1951)

Barry James Marshall is an Australian physician, Nobel Prize Laureate in Physiology or Medicine, Professor of Clinical Microbiology and Co-Director of the Marshall Centre at the University of Western Australia. Marshall and Robin Warren showed that the bacterium Helicobacter pylori plays a major role in causing many peptic ulcers, challenging decades of medical doctrine holding that ulcers were caused primarily by stress, spicy foods, and too much acid. This discovery has allowed for a breakthrough in understanding a causative link between Helicobacter pylori infection and stomach cancer.

<span class="mw-page-title-main">Tomica Milosavljević</span>

Tomica Milosavljević is a Serbian doctor and politician. He served as Minister of Health in the Government of Serbia under four Prime Ministers with the total span of seven years. He is also employed as a full professor at the University of Belgrade and works in the Clinical Centre of Serbia in Belgrade.

<span class="mw-page-title-main">Famotidine</span> Medication that reduces stomach acid

Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.

<span class="mw-page-title-main">Gastritis</span> Stomach disease that is an inflammation of the lining of the stomach

Gastritis is inflammation of the lining of the stomach. It may occur as a short episode or may be of a long duration. There may be no symptoms but, when symptoms are present, the most common is upper abdominal pain. Other possible symptoms include nausea and vomiting, bloating, loss of appetite and heartburn. Complications may include stomach bleeding, stomach ulcers, and stomach tumors. When due to autoimmune problems, low red blood cells due to not enough vitamin B12 may occur, a condition known as pernicious anemia.

<span class="mw-page-title-main">Achlorhydria</span> Medical condition

Achlorhydria and hypochlorhydria refer to states where the production of hydrochloric acid in gastric secretions of the stomach and other digestive organs is absent or low, respectively. It is associated with various other medical problems.

<span class="mw-page-title-main">Strongyloidiasis</span> Medical condition

Strongyloidiasis is a human parasitic disease caused by the nematode called Strongyloides stercoralis, or sometimes the closely related S. fülleborni. These helminths belong to a group of nematodes called roundworms. These intestinal worms can cause a number of symptoms in people, principally skin symptoms, abdominal pain, diarrhea and weight loss, but also many other specific and vague symptoms in disseminated disease, and severe life-threatening conditions through hyperinfection. In some people, particularly those who require corticosteroids or other immunosuppressive medication, Strongyloides can cause a hyperinfection syndrome that can lead to death if untreated. The diagnosis is made by blood and stool tests. The medication ivermectin is widely used to treat strongyloidiasis.

<span class="mw-page-title-main">MALT lymphoma</span> Medical condition

MALT lymphoma is a form of lymphoma involving the mucosa-associated lymphoid tissue (MALT), frequently of the stomach, but virtually any mucosal site can be affected. It is a cancer originating from B cells in the marginal zone of the MALT, and is also called extranodal marginal zone B cell lymphoma.

<span class="mw-page-title-main">Fecal microbiota transplant</span> Process of transplantation of fecal bacteria from a healthy individual into a recipient

Fecal microbiota transplant (FMT), also known as a stool transplant, is the process of transferring fecal bacteria and other microbes from a healthy individual into another individual. FMT is an effective treatment for Clostridioides difficile infection (CDI). For recurrent CDI, FMT is more effective than vancomycin alone, and may improve the outcome after the first index infection.

<span class="mw-page-title-main">Giaconda (pharmaceutical company)</span>

Giaconda is an Australian biotechnology company headquartered in Sydney. The company was founded in 2004 to commercialise a number of drug combinations developed by Professor Thomas Borody, a Sydney-based gastroenterologist.

Timeline of peptic ulcer disease and <i>Helicobacter pylori</i>

This is a timeline of the events relating to the discovery that peptic ulcer disease and some cancers are caused by H. pylori. In 2005, Barry Marshall and Robin Warren were awarded the Nobel Prize in Physiology or Medicine for their discovery that peptic ulcer disease (PUD) was primarily caused by Helicobacter pylori, a bacterium with affinity for acidic environments, such as the stomach. As a result, PUD that is associated with H. pylori is currently treated with antibiotics used to eradicate the infection. For decades prior to their discovery, it was widely believed that PUD was caused by excess acid in the stomach. During this time, acid control was the primary method of treatment for PUD, to only partial success. Among other effects, it is now known that acid suppression alters the stomach milieu to make it less amenable to H. pylori infection.

<span class="mw-page-title-main">Carcinogenic bacteria</span>

Cancer bacteria are bacteria infectious organisms that are known or suspected to cause cancer. While cancer-associated bacteria have long been considered to be opportunistic, there is some evidence that bacteria may be directly carcinogenic. The strongest evidence to date involves the bacterium H. pylori and its role in gastric cancer.

Helicobacter pylori eradication protocols is a standard name for all treatment protocols for peptic ulcers and gastritis in the presence of Helicobacter pylori infection. The primary goal of the treatment is not only temporary relief of symptoms but also total elimination of H. pylori infection. Patients with active duodenal or gastric ulcers and those with a prior ulcer history should be tested for H. pylori. Appropriate therapy should be given for eradication. Patients with MALT lymphoma should also be tested and treated for H. pylori since eradication of this infection can induce remission in many patients when the tumor is limited to the stomach. Several consensus conferences, including the Maastricht Consensus Report, recommend testing and treating several other groups of patients but there is limited evidence of benefit. This includes patients diagnosed with gastric adenocarcinoma, patients found to have atrophic gastritis or intestinal metaplasia, as well as first-degree relatives of patients with gastric adenocarcinoma since the relatives themselves are at increased risk of gastric cancer partly due to the intrafamilial transmission of H. pylori. To date, it remains controversial whether to test and treat all patients with functional dyspepsia, gastroesophageal reflux disease, or other non-GI disorders as well as asymptomatic individuals.

<span class="mw-page-title-main">Giovanni Gasbarrini</span> Italian physician

Giovanni Gasbarrini is an Italian physician whose work in the field of internal medicine, hepatology and gastroenterology earned him the 2013 lifetime achievement award of the United European Gastroenterology (UEG) association.

Richard Ferrero is a microbiologist. He is a senior research fellow of the National Health and Medical Research Council (NHMRC). In the Centre for Innate Immunity and Infectious Diseases at the Hudson Institute, he also holds the position of senior scientist and head of the Gastrointestinal Infection and Inflammation Research Group.

<span class="mw-page-title-main">Ivermectin during the COVID-19 pandemic</span> Uses of drug ivermectin during the COVID-19 pandemic

Ivermectin is an antiparasitic drug that is well established for use in animals and people. The World Health Organization (WHO), the European Medicines Agency (EMA), the United States Food and Drug Administration (FDA), and the Infectious Diseases Society of America (IDSA) all advise against using ivermectin in an attempt to treat or prevent COVID-19.

References

  1. 1 2 3 "Doctor who advocated Covid-19 therapy including ivermectin applied for patent on same unproven treatment". The Guardian. 18 October 2021. Retrieved 18 October 2021.
  2. 1 2 3 Alexander, Harriet (22 October 2021). "How a false science 'cure' became Australia's contribution to the pandemic". Sydney Morning Herald .
  3. 1 2 3 Siegel-Itzkovich, Judy (24 November 2013). "He has the stomach for it". Jerusalem Post. Retrieved 30 January 2022.
  4. "Fellows of the Royal Society of NSW (B)". Royal Society of New South Wales. Archived from the original on 30 June 2021. Retrieved 2 July 2021.
  5. Kremer, William (27 May 2014). "The brave new world of DIY faecal transplant". BBC World Service.
  6. 1 2 "Topelia Australia launches US$25M Series A call for COVID-19 ATT Ziverdox". BioSpace. Retrieved 18 October 2021.
  7. "COVID-19 treatments". Australian Government Department of Health. 22 December 2021.